MedTrace Logo

Efficacy and Safety of Antidepressant Augmentation With Lamotrigine

NCT00652171 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2008-04-09

No results posted yet for this study

Summary

This study reports a clinical trial evaluating lamotrigine safety and efficacy as an antidepressant augmentation agent in treatment resistant depression, therefore adding more empirical evidence to the limited number of studies on the use of lamotrigine.

Conditions

Interventions

DRUG

Lamotrigine

Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.

DIETARY_SUPPLEMENT

Amide

Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.

Sponsors & Collaborators

  • Institute of Social Security of the Civil Servants of Minas Gerais

    lead OTHER_GOV

Principal Investigators

  • Milena A Santos, Master · City Hall of Beló Horizonte

  • Claudia Hara, Master · Faculdade de Saúde e Ecologia Humana

  • Fabio L Rocha, PhD · Institute of Social Security of the Civil Servants of Minas Gerais

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2006-01-31
Completion
2006-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652171 on ClinicalTrials.gov